Abstract:Disease progression in a cancer patient are identified by a number of indications in the form of loco-regional relapse, distant metastasis etc. Biomarkers play an essential role in early identification of these indications. The biomarkers can influence how a particular cancer behaves and how it may respond to a specific treatment, e.g., the survival probability of breast cancer patients diagnosed with HER2 positive status is different from the same with HER2 negative status. Researches have shown that the genetic mutations are often inconsistent across tumours and this is depicted in the form of bimodal and multi-modal expression values. So, the heterogeneity of the biomarker statuses or levels should be taken into consideration while modelling the survival outcome. This heterogeneity factor which is often unobserved, is called frailty. In the presence of competing events, the scenario becomes more complex as only one of them can occur, which will censor the occurrence of other events. Incorporating independent frailties of each biomarker status for every cause of indications will not portray the complete picture of heterogeneity. The events indicating cancer progression are likely to be inter-related. So, the correlation should be incorporated through the frailties of different events. The process can be performed for a single biomarker using a competing risk model with correlated frailty and estimates are obtained using Expectation-Maximization algorithm. Based on the estimated variance of the frailty, the threshold levels of a biomarker are utilised as early detection tool of the disease progression or death. For multiple biomarkers, we have employed a sequential proportional hazard model using p-value combination method which will incorporate the correlations between the biomarkers. With the extensive algorithm in R, we have obtained the threshold levels of activity of multiple biomarkers in a competing risk scenario.

Spondylolisthesis after multiple bilateral laminectomies and facetectomies for lumbar spondylosis. Follow-up review.

Template and catalytic effects of DNA in the construction of polypyrrole/DNA composite macro and microelectrodes.

Individual frailty excess hazard models in cancer epidemiology

A study on comparisons of additive regression frailty models to counter heterogeneity: Bayesian strategies and case study

Correlated gamma frailty models for bivariate survival time data

A modified risk detection approach of biomarkers by frailty effect on multiple time to event data

Impact of model misspecification in shared frailty survival models

Correcting for heterogeneity and non-comparability bias in multicenter clinical trials with a rescaled random-effect excess hazard model

Modeling county level breast cancer survival data using a covariate-adjusted frailty proportional hazards model

Joint modelling of recurrent and terminal events with discretely-distributed non-parametric frailty: application on re-hospitalizations and death in heart failure patients

[On the pathogenesis and morphogenesis of cystic kidneys].

Frailty Model with Change Point for Survival Analysis

Survival Analysis in the Presence of Competing Risks

The shape of the relative frailty variance induced by discrete random effect distributions in univariate and multivariate survival models

Long-Term Dagum-PVF Frailty Regression Model: Application in Health Studies

Characterization of cytoskeletal protein 4.1R interaction with NHE1 (Na(+)/H(+) exchanger isoform 1).

On the Addams family of discrete frailty distributions for modelling multivariate case I interval-censored data

Frailty Models for Pneumonia to Death with a Left‐censored Covariate

Birnbaum–Saunders frailty regression models for clustered survival data

Hierarchical models for semi-competing risks data with application to quality of end-of-life care for pancreatic cancer

Parametric Analysis of Bivariate Current Status data with Competing risks using Frailty model